Infliximab-Associated Hepatic Injury in Crohn’s Disease

Authors

  • Sura A. Abdulsattar1 , Raghd A.Y. Alkhader2 , Haider Ridha Mohammed Saeed3 , Fatin F. AlKazazz4

DOI:

https://doi.org/10.37506/mlu.v21i1.2449

Keywords:

Aminotransferase, autoimmune hepatitis, Cholestatic, Crohn’s, hepatocellular, inflammatory bowel disease, Infliximab, liver

Abstract

Hepatotoxicity disorders are relatively common in patients with inflammatory bowel disease that includes
ulcerative colitis and Crohn’s disease. Abnormal serum liver functions tests can develop during treatment with
(TNF-?) blocking agents, such as, Infliximab. The aim of this review is to clarify the role of infliximab in the
development of liver enzyme abnormalities in patients with Crohn’s disease. The most common presentation
of infliximab -associated liver injury is a hepatocellular type with auto-immune features, marked by
increased serum aminotransferases levels. Cholestatic injury is much less common, and marked by jaundice
and increased serum ALP and bilirubin levels,with elevations of serum ALT and AST. Abnormalities of liver
function tests in sera of patients with Crohn’s disease typically resolve after discontinuation of infliximab,
although sever liver injury leading to liver transplant cannot be ruled out.

Author Biography

Sura A. Abdulsattar1 , Raghd A.Y. Alkhader2 , Haider Ridha Mohammed Saeed3 , Fatin F. AlKazazz4

1Professor, 2Assistant Tutor, 3Assistant Tutor, Department of Chemistry and Biochemistry, College of Medicine,
Mustansiriyah University, Baghdad, Iraq, 4Professor, Department of Chemistry, College of Science,
Mustansiriyah University, Baghdad, Iraq

Published

2021-01-09

How to Cite

Sura A. Abdulsattar1 , Raghd A.Y. Alkhader2 , Haider Ridha Mohammed Saeed3 , Fatin F. AlKazazz4. (2021). Infliximab-Associated Hepatic Injury in Crohn’s Disease. Medico Legal Update, 21(1), 1012-1017. https://doi.org/10.37506/mlu.v21i1.2449

Most read articles by the same author(s)